Esomeprazole for the treatment of erosive esophagitis in children: An international, multicenter, randomized, parallel-group, double-blind (for dose) study

BMC Pediatrics

Volumn 10, Issue , 2010, Pages

  Tolia, Vasundhara ^a,e   Youssef, Nader N ^b,d   Gilger, Mark A ^c   Traxler, Barry ^d   Illueca, Marta ^d  

^a WAYNE STATE UNIVERSITY   (United States)

^b Atlantic Health   (United States)

^c BAYLOR COLLEGE OF MEDICINE   (United States)

^d ASTRAZENECA   (United Kingdom)

^e PROVIDENCE HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALUMINUM MAGNESIUM HYDROXIDE; ESOMEPRAZOLE; ANTIULCER AGENT; OMEPRAZOLE; PROTON PUMP INHIBITOR;

ARTICLE; CHILD; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DOUBLE BLIND PROCEDURE; ENDOSCOPY; FOLLOW UP; GASTROESOPHAGEAL REFLUX; HEADACHE; HISTOLOGY; HUMAN; MAJOR CLINICAL STUDY; MULTICENTER STUDY; RANDOMIZED CONTROLLED TRIAL; REFLUX ESOPHAGITIS; SOMNOLENCE; ESOPHAGOSCOPY; FEMALE; INFANT; MALE; PATHOLOGY; PRESCHOOL CHILD;

ANTI-ULCER AGENTS; CHILD; CHILD, PRESCHOOL; DOUBLE-BLIND METHOD; ESOPHAGITIS, PEPTIC; ESOPHAGOSCOPY; FEMALE; HUMANS; INFANT; MALE; OMEPRAZOLE; PROTON PUMP INHIBITORS;

EID: 77954884122     PISSN: None     EISSN: 14712431     Source Type: Journal    
DOI: 10.1186/1471-2431-10-41     Document Type: Article

References (39)

1. Chitkara DK, Talley NJ, Weaver AL, Katusic SK, De Schepper H, Rucker MJ, Locke GR. Incidence of presentation of common functional gastrointestinal disorders in children from birth to 5 years: a cohort study. Clin Gastroenterol Hepatol 2007, 5:186-191. 10.1016/j.cgh.2006.06.012, 16901769.
2. El-Serag HB, Bailey NR, Gilger M, Rabeneck L. Endoscopic manifestations of gastroesophageal reflux disease in patients between 18 months and 25 years without neurological deficits. Am J Gastroenterol 2002, 97:1635-1639. 10.1111/j.1572-0241.2002.05820.x, 12135011.
3. Gilger MA, El-Serag HB, Gold BD, Dietrich CL, Tsou V, McDuffie A, Shub MD. Prevalence of endoscopic findings of erosive esophagitis in children: a population-based study. J Pediatr Gastroenterol Nutr 2008, 47:141-146. 10.1097/MPG.0b013e31815eeabe, 18664864.
4. Rudolph CD, Mazur LJ, Liptak GS, Baker RD, Boyle JT, Colletti RB, Gerson WT, Werlin SL. Guidelines for evaluation and treatment of gastroesophageal reflux in infants and children: recommendations of the North American Society for Pediatric Gastroenterology and Nutrition. J Pediatr Gastroenterol Nutr 2001, 32(suppl 2):S1-S31. 10.1097/00005176-200100002-00001, 11525610.
5. Dahms BB. Reflux esophagitis: sequelae and differential diagnosis in infants and children including eosinophilic esophagitis. Pediatr Dev Pathol 2004, 7:5-16. 10.1007/s10024-003-0203-5, 15255030.
6. Ravelli AM, Villanacci V, Ruzzenenti N, Grigolato P, Tobanelli P, Klersy C, Rindi G. Dilated intercellular spaces: a major morphological feature of esophagitis. J Pediatr Gastroenterol Nutr 2006, 42:510-515. 10.1097/01.mpg.0000215312.78664.b9, 16707972.
7. DeVault KR, Castell DO. Updated guidelines for the diagnosis and treatment of gastroesophageal reflux disease. Am J Gastroenterol 2005, 100:190-200. 10.1111/j.1572-0241.2005.41217.x, 15654800.
8. Kahrilas PJ, Falk GW, Johnson DA, Schmitt C, Collins DW, Whipple J, D'Amico D, Hamelin B, Joelsson B. Esomeprazole improves healing and symptom resolution as compared with omeprazole in reflux oesophagitis patients: a randomized controlled trial. The Esomeprazole Study Investigators. Aliment Pharmacol Ther 2000, 14:1249-1258. 10.1046/j.1365-2036.2000.00856.x, 11012468.
9. Richter JE, Kahrilas PJ, Johanson J, Maton P, Breiter JR, Hwang C, Marino V, Hamelin B, Levine JG, . Esomeprazole Study Investigators Efficacy and safety of esomeprazole compared with omeprazole in GERD patients with erosive esophagitis: a randomized controlled trial. Am J Gastroenterol 2001, 96:656-665. 10.1111/j.1572-0241.2001.03600.x, 11280530, Esomeprazole Study Investigators.
10. Castell DO, Kahrilas PJ, Richter JE, Vakil NB, Johnson DA, Zuckerman S, Skammer W, Levine JG. Esomeprazole (40 mg) compared with lansoprazole (30 mg) in the treatment of erosive esophagitis. Am J Gastroenterol 2002, 97:575-583. 10.1111/j.1572-0241.2002.05532.x, 11922549.
11. Fennerty MB, Johanson JF, Hwang C, Sostek M. Efficacy of esomeprazole 40 mg vs. lansoprazole 30 mg for healing moderate to severe erosive oesophagitis. Aliment Pharmacol Ther 2005, 21:455-463. 10.1111/j.1365-2036.2005.02339.x, 15709997.
12. Labenz J, Armstrong D, Lauritsen K, Katelaris P, Schmidt S, Schütze K, Wallner G, Juergens H, Preiksaitis H, Keeling N, Nauclér E, Eklund S, . Expo Study Investigators A randomized comparative study of esomeprazole 40 mg versus pantoprazole 40 mg for healing erosive oesophagitis: the EXPO study. Aliment Pharmacol Ther 2005, 21:739-746. 10.1111/j.1365-2036.2005.02368.x, 15771760, Expo Study Investigators.
13. Zhao J, Li J, Hamer-Maansson JE, Andersson T, Fulmer R, Illueca M, Lundborg P. Pharmacokinetic properties of esomeprazole in children aged 1 to 11 years with symptoms of gastroesophageal reflux disease: a randomized, open-label study. Clin Ther 2006, 28:1868-1876. 10.1016/j.clinthera.2006.11.012, 17213007.
14. Gilger MA, Tolia V, Vandenplas Y, Youssef NN, Traxler B, Illueca M. Safety and tolerability of esomeprazole in children with gastroesophageal reflux disease. J Pediatr Gastroenterol Nutr 2008, 46:524-533. 10.1097/MPG.0b013e318176b2cb, 18493207.
15. Lundell LR, Dent J, Bennett JR, Armstrong D, Galmiche JP, Johnson F, Hongo M, Richter JE, Spechler SJ, Tytgat GN, Wallin L. Endoscopic assessment of oesophagitis: clinical and functional correlates and further validation of the Los Angeles classification. Gut 1999, 45:172-180. 10.1136/gut.45.2.172, 1727604, 10403727.
16. Liacouras CA, Wenner WJ, Brown K, Ruchelli E. Primary eosinophilic esophagitis in children: successful treatment with oral corticosteroids. J Pediatr Gastroenterol Nutr 1998, 26:380-385. 10.1097/00005176-199804000-00004, 9552132.
17. Ruchelli E, Wenner W, Voytek T, Brown K, Liacouras C. Severity of esophageal eosinophilia predicts response to conventional gastroesophageal reflux therapy. Pediatr Dev Pathol 1999, 2:15-18. 10.1007/s100249900084, 9841701.
18. Gilger MA, El-Serag HB, Dietrich CL, Gold BD, Hassall EG. Endoscopic manifestations of erosive esophagitis in children [abstract]. Gastrointest Endosc 2004, 59:143. 10.1016/S0016-5107(04)00691-1, 14722572.
19. Gupta SK, Fitzgerald JF, Chong SKF, Croffie JM, Collins MH. Vertical lines in distal esophageal mucosa (VLEM): a true endoscopic manifestation of esophagitis in children?. Gastrointest Endosc 1997, 45:485-489. 10.1016/S0016-5107(97)70178-0, 9199905.
20. Squires RH, Colletti RB. Indications for pediatric gastrointestinal endoscopy: a medical position statement of the North American Society for Pediatric Gastroenterology and Nutrition. J Pediatr Gastroenterol Nutr 1996, 23:107-110. 10.1097/00005176-199608000-00002, 8856574.
21. Winter HS, Madara JL, Stafford RJ, Grand RJ, Quinlan JE, Goldman H. Intraepithelial eosinophils: a new diagnostic criterion for reflux esophagitis. Gastroenterology 1982, 83:818-823.
22. Black DD, Haggitt RC, Orenstein SR, Whitington PF. Esophagitis in infants. Morphometric histological diagnosis and correlation with measures of gastroesophageal reflux. Gastroenterology 1990, 98:1408-1414.
23. Shub MD, Ulshen MH, Hargrove CB, Siegal GP, Groben PA, Askin FB. Esophagitis: a frequent consequence of gastroesophageal reflux in infancy. J Pediatr 1985, 107:881-884. 10.1016/S0022-3476(85)80180-3, 4067745.
24. Ismail-Beigi F, Horton PF, Pope CE. Histological consequences of gastroesophageal reflux in man. Gastroenterology 1970, 58:163-174.
25. Ismail-Beigi F, Pope CE. Distribution of the histological changes of gastroesophageal reflux in the distal esophagus of man. Gastroenterology 1974, 66:1109-1113.
26. Solcia E, Villani L, Luinetti O, Trespi E, Strada E, Tinelli C, Fiocca R. Altered intercellular glycoconjugates and dilated intercellular spaces of esophageal epithelium in reflux disease. Virchows Arch 2000, 436:207-216. 10.1007/s004280050032, 10782878.
27. Croom KF, Scott LJ. Lansoprazole: in the treatment of gastro-oesophageal reflux disease in children and adolescents. Drugs 2005, 65:2129-2135. 10.2165/00003495-200565150-00005, 16225368.
28. De Giacomo C, Bawa P, Franceschi M, Luinetti O, Fiocca R. Omeprazole for severe reflux esophagitis in children. J Pediatr Gastroenterol Nutr 1997, 24:528-532. 10.1097/00005176-199705000-00007, 9161946.
29. Faure C, Michaud L, Khan Shaghaghi E, Popon M, Laurence M, Mougenot JF, Hankard R, Navarro J, Jacoz-Aigrain E. Lansoprazole in children: pharmacokinetics and efficacy in reflux oesophagitis. Aliment Pharmacol Ther 2001, 15:1397-1402. 10.1046/j.1365-2036.2001.01076.x, 11552911.
30. Franco MT, Salvia G, Terrin G, Spadaro R, De Rosa I, Iula VD, Cucchiara S. Lansoprazole in the treatment of gastro-oesophageal reflux disease in childhood. Dig Liver Dis 2000, 32:660-666. 10.1016/S1590-8658(00)80326-6, 11142573.
31. Hassall E, Israel D, Shepherd R, Radke M, Dalväg A, Sköld B, Junghard O, Lundborg P. Omeprazole for treatment of chronic erosive esophagitis in children: a multicenter study of efficacy, safety, tolerability and dose requirements. International Pediatric Omeprazole Study Group. J Pediatr 2000, 137:800-807. 10.1067/mpd.2000.109607, 11113836.
32. Madrazo-de la Garza A, Dibildox M, Vargas A, Delgado J, Gonzalez J, Yañez P. Efficacy and safety of oral pantoprazole 20 mg given once daily for reflux esophagitis in children. J Pediatr Gastroenterol Nutr 2003, 36:261-265. 10.1097/00005176-200302000-00019, 12548064.
33. Tolia V, Bishop PR, Marc Tsou V, Gremse D, Soffer EF, Comer GM, . Members of the 322 Study Group Multicenter, randomized, double-blind study comparing 10, 20 and 40 mg pantoprazole in children (5-11 years) with symptomatic gastroesophageal reflux disease. J Pediatr Gastroenterol Nutr 2006, 42:384-391. 10.1097/01.mpg.0000214160.37574.d3, 16641576, Members of the 322 Study Group.
34. Tolia V, Ferry G, Gunasekaran T, Huang B, Keith R, Book L. Efficacy of lansoprazole in the treatment of gastroesophageal reflux disease in children. J Pediatr Gastroenterol Nutr 2002, 35(suppl 4):S308-S318.
35. Vandenplas Y, Ashkenazi A, Belli D, Boige N, Bouquet J, Cadranel S, Cezard JP, Cucchiara S, Dupont C, Geboes K, Gottrand F, Heymans HSA, Jasinski C, Kneepkens CMF, Koletzko S, Milla P, Mougenot JF, Nusslé D, Navarro J, Newell SJ, Olafsdottir E, Peeters S, Ravelli A, Polanco I, Sandhu BK, Tolboom J. A proposition for the diagnosis and treatment of gastro-oesophageal reflux disease in children: a report from a working group on gastro-oesophageal reflux disease. Working Group of the European Society of Paediatric Gastro-enterology and Nutrition (ESPGAN). Eur J Pediatr 1993, 152:704-711. 10.1007/BF01953980, 8223796.
36. Youssef NN, Orenstein SR. Gastroesophageal reflux disease in children. Clin Perspect Gastroenterol 2001, Jan/Feb:11-17.
37. International Conference on Harmonisation (ICH) of Technical Requirements for Registration of Pharmaceuticals for Human Use ICH Harmonised Tripartite Guideline: Clinical Investigation for Medicinal Products in the Pediatric Population 2000, E11. International Conference on Harmonisation (ICH) of Technical Requirements for Registration of Pharmaceuticals for Human Use.
38. Tolia V, Youssef N, Belknap W, Gilger M, Traxler B, Illueca M. Treatment of erosive esophagitis with esomeprazole in children with gastroesophageal reflux disease. Poster presented at North American Society for Pediatric Gastroenterology, Hepatology, & Nutrition (NASPGHAN) Annual Meeting, October 19-22, 2006, Orlando, FL
39. Tolia V, Youssef N, Belknap W, Gilger M, Traxler B, Illueca M. Treatment of erosive esophagitis with esomeprazole in children with gastroesophageal reflux disease. J Pediatr Gastroenterol Nutr 2006, 43:E20.